- USDA Gets Tougher on Salmonella in Raw Breaded Chicken Products
- Fragments of Bird Flu Virus Found in 1 in 5 Milk Samples
- Clients Got HIV Through ‘Vampire Facial’ Microneedling Treatments
- Take the Stairs & Step Up to Longer Life
- ‘Drug Take Back Day’ is Saturday: Check for Leftover Opioids in Your Home
- Loneliness Can Shorten Lives of Cancer Survivors
- A Stolen Dog Feels Like Losing a Child, Study Finds
- Healthier Hearts in Middle Age Help Black Women’s Brains Stay Strong
- Better Scans Spot Hidden Inflammation in MS Patients
- Which Patients and Surgeries Are ‘High Risk’ for Seniors?
Empliciti Approved for Multiple Myeloma
Empliciti (elotuzumab), in combination with two other drugs, has been approved by the U.S. Food and Drug Administration to treat the blood cancer multiple myeloma. The drug is only approved for patients who have already been given one-to-three prior therapies for the disease.
Multiple myeloma is a type of cancer that affects germ-fighting white blood cells produced in bone marrow. Symptoms typically include a weakened immune system and bone and kidney problems. Nearly 27,000 new cases are projected in the United States, and more than 11,000 will die from it this year, the National Cancer Institute estimates.
Empliciti directs the immune system to kill multiple myeloma cells, the FDA explained Monday in a news release. It is approved in combination with another anti-cancer drug, Revlimid (lenalidomide), and the corticosteroid dexamethasone.
Empliciti was evaluated in clinical studies involving more than 640 people whose multiple myeloma returned or didn’t respond to prior treatment. People who took the three-drug combination including Empliciti had an average disease-progression delay of 19.4 months, compared to about 15 months among those who took the other two drugs without Empliciti.
Empliciti’s most common side effects included fatigue, diarrhea, fever, constipation, cough, nerve damage in the arms and legs, nasal infection, respiratory infection, loss of appetite and pneumonia.
The drug is marketed by New York City-based Bristol-Myers Squibb.
More information
Visit the FDA to learn more.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.